Public Employees Retirement System of Ohio Has $26.93 Million Stock Holdings in Cencora, Inc. $COR

Public Employees Retirement System of Ohio reduced its stake in Cencora, Inc. (NYSE:CORFree Report) by 3.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,723 shares of the company’s stock after selling 2,902 shares during the period. Public Employees Retirement System of Ohio’s holdings in Cencora were worth $26,929,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Kemnay Advisory Services Inc. acquired a new stake in shares of Cencora in the 4th quarter valued at about $25,000. Oakworth Capital Inc. bought a new stake in Cencora in the 4th quarter valued at about $26,000. Elyxium Wealth LLC acquired a new position in Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp raised its stake in Cencora by 134.3% during the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after buying an additional 47 shares during the period. Finally, Motiv8 Investments LLC bought a new position in Cencora in the fourth quarter worth approximately $29,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other news, Director Lauren M. Tyler acquired 550 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director directly owned 4,359 shares of the company’s stock, valued at $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of a number of research reports. Bank of America raised their price objective on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a research note on Wednesday, June 24th. Wells Fargo & Company lowered their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Barclays cut their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a report on Wednesday, June 10th. Morgan Stanley set a $342.00 price target on shares of Cencora in a research report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 30th. Eleven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

Check Out Our Latest Stock Analysis on Cencora

Cencora Price Performance

COR stock opened at $309.67 on Friday. The company has a debt-to-equity ratio of 3.40, a quick ratio of 0.59 and a current ratio of 0.95. The business has a 50-day simple moving average of $284.52 and a two-hundred day simple moving average of $316.47. The company has a market capitalization of $60.25 billion, a P/E ratio of 23.75, a price-to-earnings-growth ratio of 1.69 and a beta of 0.58. Cencora, Inc. has a 52-week low of $244.82 and a 52-week high of $377.54.

Cencora (NYSE:CORGet Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Research analysts expect that Cencora, Inc. will post 17.79 EPS for the current fiscal year.

Cencora declared that its board has authorized a share repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is 18.40%.

Cencora Company Profile

(Free Report)

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Featured Articles

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.